Ampio Class Action Complaint Filed: Johnson Fistel,
SAN DIEGO, Aug. 17, 2022 (GLOBE NEWSWIRE) — Law firm specializing in shareholder rights Johnson Fistel, LLP announces that a class action lawsuit has been filed on behalf of the investors of Ampio Pharmaceuticals, Inc. (“Ampio”) (US NYSE: AMPE). The class action is on behalf of shareholders who purchased or otherwise acquired the shares between December 29, 2020 and August 3, 2022. Investors are hereby notified that they have until October 17, 2022 to ask the court to serve lead plaintiff in this action. .
What actions can I take at this time? If you have suffered a loss and would like to learn more about the lead plaintiff role, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If emailing, please include a phone number.
To join this action, you can click or copy and paste the link below into a browser:
There is no cost or obligation for you.
The lawsuit stems from the company’s misrepresentations regarding the ability of Ampion, its lead product, to treat people with inflammatory conditions, including but not limited to severe osteoarthritis of the knee (“OAK “). From approximately 2010 to March 2022, Ampio conducted numerous clinical trials and analyzes to determine the effectiveness of Ampion. Despite confidential advertisements on numerous occasions that Ampion has demonstrated a statistically significant decrease in pain associated with moderate to severe symptomatic OAK, the company has failed to commercialize Ampion. On May 16, 2022, the company announced that it had formed a special committee to conduct internal investigations focused on the statistical analysis of Ampio’s AP-013 clinical trial and the unauthorized supply of Ampion, which does not had not yet been approved by the United States Food and Drug Administration. . Then, on August 3, 2022, Ampio disclosed that “senior management was aware at the time of the interim per-protocol analysis in March 2020 that the AP-103 trial did not demonstrate the efficacy of Ampion on its co-primary endpoints of pain and function, and that these individuals did not fully report the results of the AP-103 trial and the timing of the unblinding of the AP trial data -103.”
A lead plaintiff will act on behalf of all other class members to lead the Ampio class action. The lead plaintiff may select a law firm of their choice to litigate the class action. An investor’s ability to share in any potential future recovery from the Ampio class action does not depend on its status as lead plaintiff. For more information on the lead applicant process, please see https://www.johnsonfistel.com/lead-plaintiff-deadlines.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivatives and securities class actions. Johnson Fistel is seeking to recover losses incurred due to violations of federal securities laws. For more information about the firm and its lawyers, visit http://www.johnsonfistel.com. Lawyer advertisement. Past results do not guarantee future results.
Johnson Fistel, LLP
Jim Baker, 619-814-4471